Monoclonal antibodies in the treatment of pancreatic cancer

Immunotherapy

Volumn 1, Issue 2, 2009, Pages 223-239

  Huang, Zhi Qiang ^b   Buchsbaum, Donald J ^a  

^a Division of Radiation Biology   (United States)

^b NONE

Author keywords

Cancer therapy; Immunotherapy; Monoclonal antibody; Pancreatic cancer

Indexed keywords

AMG 655; APOMAB; CETUXIMAB; CH 806; CISPLATIN; DEATH RECEPTOR 5; DOCETAXEL; DR5 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE S 1; GEMCITABINE; IMC A12; IRINOTECAN; LEXATUMUMAB; MATUZUMAB; MONOCLONAL ANTIBODY; MORAB 009; NIMOTUZUMAB; OXALIPLATIN; PANITUMUMAB; PERTUZUMAB; RAV 12; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOMATOMEDIN C; SS1P; TIPIFARNIB; TRA 8; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DRUG POTENTIATION; FUNCTIONAL GENOMICS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRUCTURAL GENOMICS; SURVIVAL RATE; TUMOR GROWTH; TUMOR RESISTANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; PANCREATIC NEOPLASMS;

EID: 77953409481     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.2.223     Document Type: Review

References (152)

1. Brenner H, Gondos A, Arndt V: Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J. Clin. Oncol. 25, 3274-3280 (2007).
2. Shaib YH, Davila JA, El-Serag HB: The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol. Ther. 24, 87-94 (2006).
3. Steeg PS, Theodorescu D: Metastasis: a therapeutic target for cancer. Nat. Clin. Pract. Oncol. 5, 206-219 (2008).
4. Kalofonos HP, Grivas PD: Monoclonal antibodies in the management of solid tumors. Curr. Top. Med. Chem. 6, 1687-1705 (2006).
5. Schrama D, Reisfeld RA, Becker JC: Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 5, 147-159 (2006). ■■ General review of targeted therapy with antibodies for cancer treatment.
6. Di Cristina M, Minenkova O, Pavoni E et al: A novel approach for identification of tumor-associated antigens expressed on the surface of tumor cells. Int. J. Cancer 120, 1293-1303 (2007). (Pubitemid 46256783)
7. Wu AA, Niparko KJ, Pai SI: Immunotherapy for head and neck cancer. J. Biomed. Sci. 15, 275-289 (2008).
8. Adams GP, Weiner LM: Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-1157 (2005).
9. Albrecht H, DeNardo SJ: Recombinant antibodies: from the laboratory to the clinic. Cancer Biother. Radiopharm. 21, 285-304 (2006).
10. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ: Immunotoxin therapy of cancer. Nat. Rev. Cancer 6, 559-565 (2006).
11. Karacay H, Brard PY, Sharkey RM et al.: Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin. Cancer Res. 11, 7879-7885 (2005).
12. Huang Z-q, Buchsbaum DJ, Raisch KP et al.: Differential responses by pancreatic carcinoma cell lines to prolonged exposure to erbitux (IMC-C225) anti-EGFR antibody. J. Surg. Res. 111, 274-283 (2003).
13. Cascinu S, Berardi R, Labianca R et al.: Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, Phase II trial. Lancet Oncol. 9, 39-44 (2008). ■ Negative Phase II study results.
14. Xiong HQ, Rosenberg A, LoBuglio A et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol. 22, 2610-2616 (2004).
15. Burtness BA, Powell M, Berlin J et al.: Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r). J. Clin. Oncol. 25, 4519 (2007).
16. Kullmann F, Hollerbach S, Dollinger M et al.: Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in 1st line metastatic pancreatic cancer, first results from a multicenter Phase II study. Presented at: 2007 Gastrointestinal Cancers Symposium. (Abstract 128) (2007). ■ Phase II study from a large population.
17. Morgan MA, Parsels LA, Kollar LE et al.: The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin. Cancer Res. 14, 5142-5149 (2008).
18. Philip P, Benedetti J, Fenoglio-Preiser C et al.: Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S0205 study. J. Clin. Oncol. 25, LBA 4509 (2007).
19. Diaz RM, Bateman A, Emiliusen L et al.: A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther. 7, 1656-1663 (2000). (Pubitemid 30814614)
20. Jimeno A, Tan AC, Coffa J et al.: Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res. 68, 2841-2849 (2008).
21. Rivera F, Vega-Villegas ME, Lopez-Brea MF: Cetuximab, its clinical use and future perspectives. Anticancer Drugs 19, 99-113 (2008).
22. Kang SP, Saif MW: Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP 9, 251-266 (2008).
23. Weiner LM, Belldegrun AS, Crawford J et al.: Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin. Cancer Res. 14, 502-508 (2008).
24. Graeven U, Kremer B, Sudhoff T et al.: Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br. J. Cancer 94, 1293-1299 (2006).
25. Vanhoefer U, Tewes M, Rojo F et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 22, 175-184 (2004).
26. Burris HA, Moore MJ, Andersen J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997).
27. Akashi Y, Okamoto I, Iwasa T et al.: Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br. J. Cancer 98, 749-755 (2008).
28. Scott AM, Lee FT, Tebbutt N et al.: A Phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl Acad. Sci. USA 104, 4071-4076 (2007).
29. Tsiambas E, Karameris A, Dervenis C et al.: HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP 7, 283-294 (2006).
30. Saeki H, Yanoma S, Takemiya S et al.: Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. Oncol. Rep. 18, 433-439 (2007).
31. Kimura K, Sawada T, Komatsu M et al.: Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin. Cancer Res. 12, 4925-4932 (2006).
32. Larbouret C, Robert B, Navarro-Teulon I et al.: In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin. Cancer Res. 13, 3356-3362 (2007).
33. Cengel KA, Voong KR, Chandrasekaran S et al: Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 9, 341-348 (2007). (Pubitemid 46608301)
34. Kumagai T, Wakimoto N, Yin D et al.: Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat®, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer 121, 656-665 (2007). (Pubitemid 46986501)
35. Parihar R, Nadella P, Lewis A et al.: A Phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon-γ production in a subset of patients. Clin. Cancer Res. 10, 5027-5037 (2004).
36. Franklin MC, Carey KD, Vajdos FF et al.: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5, 317-328 (2004).
37. Agus DB, Gordon MS, Taylor C et al.: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. 23, 2534-2543 (2005).
38. Aggarwal BB, Bhardwaj U, Takada Y: Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam. Harm. 67, 453-483 (2004).
39. Debatin K-M, Krammer PH: Death receptors in chemotherapy and cancer. Oncogene 23, 2950-2966 (2004).
40. Varfolomeev EE, Ashkenazi A: Tumor necrosis factor: an apoptosis JuNKie? Cell 116, 491-497 (2004).
41. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 95, 777-783 (2004). (Pubitemid 39545582)
42. Rudner J, Jendrossek V, Lauber K et al.: Type I and type II reactions in TRAIL-induced apoptosis -results from dose-response studies. Oncogene 24, 130-140 (2005). (Pubitemid 40143872)
43. Buchsbaum DJ, Zhou T, LoBuglio AF: TRAIL receptor-targeted therapy. Future Oncol. 2, 493-508 (2006).
44. Yada A, Yazawa M, Ishida S et al.: A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann. Oncol. 19, 1060-1067 (2008).
45. Buchsbaum DJ, Zhou T, Grizzle WE et al.: Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 9, 3731-3741 (2003).
46. Ohtsuka T, Buchsbaum D, Oliver P et al.: Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22, 2034-2044 (2003). (Pubitemid 36523640)
47. DeRosier LC, Vickers SM, Zinn KR et al.: TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol. Cancer Ther. 6, 3198-3207 (2007).
48. DeRosier LC, Huang Z-Q, Sellers JC, Buchsbaum DJ, Vickers SM: Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. J. Gastrointest. Surg. 10, 1291-1300 (2006).
49. DeRosier LC, Buchsbaum DJ, Oliver PG et al.: Combination treatment with TRA-8 anti-death receptor-5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin. Cancer Res. 13, S5535-S5543 (2007).
50. Kaplan-Lefko P, Bush T, Belmontes B et al. AMG 655, a fully human agonistic antibody against death receptor 5, enhances the anti-tumor activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model. Presented at: American Association for Cancer Research Annual Meeting Proceedings. San Diego, CA, USA (2008).
51. Adams C, Totpal K, Lawrence D et al.: Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ. 15, 751-761 (2008).
52. Park KJ, Lee SH, Kim TI et al.: A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res. 67, 7327-7334 (2007).
53. Plummer R, Attard G, Pacey S et al.: Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13, 6187-6194 (2007).
54. Shimada O, Wu X, Jin X et al.: Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells. Urology 69, 395-401 (2007).
55. Wang J, Lin Z, Qiao CX et al.: Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis. Cell. Mol. Immunol. 5, 55-60 (2008).
56. Hakam A, Fang Q, Karl R, Coppola D: Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig. Dis. Sci. 48, 1972-1978 (2003).
57. Neid M, Datta K, Stephan S et al.: Role of insulin receptor substrates and protein kinase C-ζ in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J. Biol. Chem. 279, 3941-3948 (2004).
58. Liu W, Bloom DA, Cance WG et al.: FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29, 1096-1107 (2008). (Pubitemid 351958687)
59. Rowinsky EK, Youssoufian H, Tonra JR et al.: IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res. 13, 5549s-5555s (2007).
60. Beltran PJ, Cajulis E, Moody G et al.: AMG 479, a fully human anti-IGF1R monoclonal antibody, Inhibits IGF-1 phospho-Akt and enhances the antineoplastic activity of cyclophosphamide in vivo (abstract). Proc. Am. Assoc. Cancer Res. nr 4001 (2008).
61. Cohen BD, Baker DA, Soderstrom C et al.: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 11, 2063-2073 (2005).
62. Pandini G, Wurch T, Akla B et al.: Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur. J. Cancer 43, 1318-1327 (2007).
63. Li JC, Li R: RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205. Cancer Res. 67, 8856-8864 (2007).
64. Loo D, Pryer N, Young P et al.: The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol. Cancer Ther. 6, 856-865 (2007).
65. Hucl T, Brody JR, Gallmeier E et al.: High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res. 67, 9055-9065 (2007). ■ Regulation of unique expression of mesothelin in cancer
66. Hassan R, Laszik ZG, Lerner M et al.: Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am. J. Clin. Pathol. 124, 838-845 (2005).
67. Hassan R, Williams-Gould J, Steinberg SM et al.: Tumor-directed radiation and the immunotoxin SSlP in the treatment of mesothelin-expressing tumor xenografts. Clin. Cancer Res. 12, 4983-4988 (2006).
68. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J: Anti-mesothelin immunotoxin SSlP in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin. Cancer Res. 13, 7166-7171 (2007).
69. Hassan R, Bullock S, Premkumar A et al.: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 13, 5144-5149 (2007).
70. Hassan R, Ebel W, Routhier EL et al.: Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 7, 20 (2007).
71. Blumenthal RD, Hansen HJ, Goldenberg DM: In vitro and in vivo anticancer efficacy of unconjugated humanized anti-CEA monoclonal antibodies. Br. J. Cancer 99, 837-838; author reply 839-840 (2008).
72. Blumenthal RD, Osorio L, Hayes MK et al.: Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol. Immunother. 54, 315-327 (2005).
73. Koppe MJ, Oyen WJ, Bleichrodt RP et al.: Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Biother. Radiopharm. 21, 506-514 (2006).
74. 1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen. Br. J. Cancer 98, 1217-1225 (2008).
75. Lutterbuese P, Brischwein K, Hofmeister R et al.: Exchanging human Feed with murine Fcα2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol. Immunother. 56, 459-468 (2007).
76. Oberneder R, Weckermann D, Ebner B et al.: A Phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur. J. Cancer 42, 2530-2538 (2006). (Pubitemid 44442943)
77. Ruan HH, Scott KR, Bautista E, Ammons WS: ING-1(heMAb), a monoclonal antibody to epithelial cell adhesion molecule, inhibits tumor metastases in a murine cancer model. Neopksia 5, 489-494 (2003).
78. Fong D, Steurer M, Obrist P et al.: Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol. 61, 31-35 (2008). (Pubitemid 351158222)
79. Macao B, Johansson DG, Hansson GC, Hard T: Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUCl mucin. Nat. Struct. Mol. Biol. 13, 71-76 (2006).
80. Levi E, Klimstra DS, Andea A, Basturk O, Adsay NV: MUC1 and MUC2 in pancreatic neoplasia. J. Clin. Pathol. 57, 456-462 (2004).
81. Patel KN, Maghami E, Wreesmann VB et al.: MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas. Surgery 138, 994-1001; discussion 1001-1002 (2005).
82. Zaretsky JZ, Barnea I, Aylon Y et al.: MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor α (ERa) in regulation of the MUC1 gene expression. Mol Cancer. 5, 57 (2006).
83. Yamada N, Nishida Y, Tsutsumida H et al.: MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res. 68, 2708-2716 (2008).
84. Swanson BJ, McDermott KM, Singh PK et al.: MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res. 67, 10222-10229 (2007).
85. Kohlgraf KG, Gawron AJ, Higashi M et al.: Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 63, 5011-5020 (2003). (Pubitemid 37022639)
86. Ahmad R, Raina D, Trivedi V et al.: MUC1 oncoprotein activates the IκB kinase κ complex and constitutive NF-κB signalling. Nat. Cell. Biol. 9, 1419-1427 (2007). ■ New role for an old molecule MUCl in a signal transduction pathway.
87. Agata N, Ahmad R, Kawano T et al.: MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res. 68, 6136-6144 (2008).
88. Yuan Z, Wong S, Borrelli A, Chung MA: Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem. Biophys. Res. Commun. 362, 740-746 (2007).
89. Gulec SC, Cohen SJ, Zuckier LS et al.: First clinical experience with 90Y-radiolabeled humanized anti-MUC1 antibody (hPAM4) in patients with advanced pancreatic cancer: a Phase I study. J. Clin. Oncol. 25, 15034 (2007).
90. Gold DV, Goldenberg DM, Karacay H et al.: A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res. 68, 4819-4826 (2008).
91. Baranowska-Kortylewicz J, Abe M, Nearman J, Enke CA: Emerging role of platelet-derived growth factor receptor-α inhibition in radioimmunotherapy of experimental pancreatic cancer. Clin. Cancer Res. 13, 299-306 (2007).
92. Mita M, Ricart A, Mita A et al.: A Phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with CanAg-expressingsolid tumors. J. Clin. Oncol. 25, (2007) (Abstract 3062).
93. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611 (2004).
94. Beckermann BM, Kallifatidis G, Groth A et al.: VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br. J. Cancer 99, 622-631 (2008).
95. Shojaei F, Ferrara N: Antiangiogenic therapy for cancer: an update. Cancer J. 13, 345-348 (2007).
96. Zhang B, Zhao WH, Zhou WY et al.: Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma. Cancer Detect. Prev. 31, 436-442 (2007).
97. Dineen SP, Lynn KD, Holloway SE et al.: Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res. 68, 4340-4346 (2008).
98. Crane CH, Ellis LM, Abbruzzese JL et al.: Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J. Clin. Oncol. 24, 1145-1151 (2006).
99. Kindler HL, Friberg G, Singh DA et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23, 8033-8040 (2005).
100. Ko AH, Dito E, Schillinger B et al.: A Phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest. New Drugs (2008).
101. Gemcitabine plus bevacizumab no better than gemcitabine alone in clinical study of 600 patients with pancreatic cancer. Cancer Biol. Ther. 6, 137 (2007). ■ Important clinical report from a large population.
102. Bhaskar V, Zhang D, Fox M et al.: A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J. Transl. Med. 5, 61 (2007).
103. Bhaskar V, Fox M, Breinberg D et al: Volociximab, a chimeric integrin α5β1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest. New Drugs 26, 7-12 (2008).
104. Evans T, Valle J, Berlin J et al.: Interim results from a Phase II study of volociximab in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC). Presented at: 2008 Gastrointestinal Cancers Symposium. (2008) (Abstract 142).
105. Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M: Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol. Cancer Ther. 5, 1108-1116 (2006).
106. Dornhofer N, Spong S, Bennewith K et al.: Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 66, 5816-5827 (2006). (Pubitemid 43927136)
107. Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A: The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin. Cancer Res. 14, 4951-4960 (2008).
108. Milowsky MI, Nanus DM, Kostakoglu L et al.: Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.J. Clin. Oncol. 25, 540-547 (2007).
109. Egberts JH, Cloosters V, Noack A et al.: Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 68, 1443-1450 (2008). (Pubitemid 351346852)
110. Robinson DW Jr, Eisenberg DF, Cella D et al.: The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J. Support. Oncol. 6, 283-290 (2008).
111. Wiedenmann B, Malfertheiner P, Friess H et al.: A multicenter, Phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.J. Support. Oncol. 6, 18-25 (2008).
112. O'Day SJ, Hamid O, Urba WJ: Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110, 2614-2627 (2007).
113. Loos M, Giese NA, Kleeff J et al.: Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett. 268, 98-109 (2008).
114. Maker AV, Phan GQ, Attia P et al.: Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12, 1005-1016 (2005).
115. Phan GQ, Weber JS, Sondak VK: CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann. Surg. Oncol. (2008).
116. Weber J: Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12, 864-872 (2007).
117. Lynch DH: The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol. Rev. 222, 277-286 (2008).
118. Hausner P, Karp J, Edelman M et al.: Phase I study of LMB-9 (B3(dsFv)PE38), a recombinant disulfide stabilized anti-Lewis Y immunotoxin administered by continuous infusion. Proc. Am. Soc. Clin. Oncol. 22, (2003).
119. Zangemeister-Wittkke U, Di Paolo C: Methods for treating cancer using an immunotoxin comprising an exotoxin A moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by MMP-2 or MMP-9. 16.02.2006, (2006) (patent).
120. Bruell D, Bruns CJ, Yezhelyev M et al.: Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int. J. Mol. Med. 15, 305-313 (2005).
121. Kreitman RJ: Immunotoxins for targeted cancer therapy. AAPS J. 8, E532-E551 (2006).
122. Moore MJ, Goldstein D, Hamm J et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007).
123. Mohla S: Tumor microenvironment. J. Cell. Biochem. 101, 801-804 (2007).
124. Ryan DP, O'Neil BH, Supko JG et al.: A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107, 2688-2697 (2006).
125. Sloss CM, Wang F, Liu R et al.: Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 14, 5116-5123 (2008).
126. Krempien R, Muenter MW, Huber PE et al.: Randomized Phase II study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer - PARC: study protocol (ISRCTN56652283). BMC Cancer 5, 131 (2005). (Pubitemid 41554899)
127. Minami H, Kawada K, Ebi H et al.: Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99, 1492-1498 (2008).
128. Siu LL, Awada A, Takimoto CH et al.: Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res. 12, 144-151 (2006).
129. Molckovsky A, Siu LL: First-in-class, first-in-human Phase I results of targeted agents: highlights of the 2008 American Society of Clinical Oncology meeting. J. Hematol. Oncol. 1, 20 (2008).
130. Kennel SJ, Brechbiel MW, Milenic DE, Schlom J, Mirzadeh S: Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49. Cancer Biother. Radiopharm. 17, 219-231 (2002).
131. Erickson HK, Park PU, Widdison WC et al.: Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426-4433 (2006).
132. Laheru D, Lutz E, Burke J et al.: Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res. 14, 1455-1463 (2008).
133. Kindler H, Bylow K, Hochster H et al.: A randomized Phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis. J. Clin. Oncol. 24, (2006) (Abstract 4040).
134. Merchan J, Venkatraman A, Macintyre J et al.: A pilot study of gemcitabine (g), oxaliplatin (o), cetuximab (c) for locally advanced or metastatic pancreatic cancer. J. Clin. Oncol. 26, (2008) (Abstract 11510).
135. Tang ZY, Wu YL, Gao SL, Shen HW: Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J. Surg. Res. 145, 111-123 (2008).
136. Preston G, Calvo E, Papadopoulos K et al.: Multi-targeted inhibition of the epidermal growth factor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: a Phase I study of cetuximab (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors. J. Clin. Oncol. 24, (2006) (Abstract 3005).
137. Chu E: Dual biologic therapy in the first-line mCRC setting: implications of the CAIR02 study. Clin. Colorectal. Cancer 7, 226 (2008).
138. Lee JJ, Chu E: An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J. 13, 276-281 (2007).
139. Rocha-Lima CM, Soares HP, Raez LE, Singal R: EGFR targeting of solid tumors. Cancer Control 14, 295-304 (2007).
140. Kindler H, Niedzwiecki D, Hollis D et al.: A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC); a preliminary analysis of cancer and Leukemia Group B (CALGB). J. Clin. Oncol. 25, (2007) (Abstract 4508).
141. Kim G, Oberg A, Foster N et al.: Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25, (2007) (Abstract 4553).
142. Iyer R, Yu j, Garrett C et al.: Multicenter phase II study of gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (APC): final analysis of clinical and quality of life endpoints. J. Clin. Oncol. 26, (2008) (Abstract 4616).
143. Moser A, Zeh H, Ramanathan R et al.: Preoperative treatment of potentially - resectable pancreatic adenocarcinoma with fixed-dose rate gemcitabine (GEM), bevacizumab (BEV), and 30 Gy radiotherapy (RT). J. Clin. Oncol. 26, 4631 (2008) (Abstract number).
144. Small W, Mulcahy M, Benson B et al.: A Phase II trial of weekly gemcitabine and bevacizumab in combination with abdominal radiation therapy in patients with localized pancreatic cancer. J. Clin. Oncol. 25, (2007) (Abstract 15043).
145. Varadhachary G, Wolff R, Crane CH et al.: Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. J. Clin. Oncol. 26, (2008) (Abstract 4630).
146. Astsaturov I, Meropol N, Alpaugh R et al.: A randomized Phase II andcoagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 25, (2007) (Abstract 4556).
147. Allegra C, Yothers G, O'connell M, Sharif S, Wolmark N: Initial safety report of NSABP C-08, a randomized Phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. J. Clin. Oncol. 26, (2008) (Abstract 4006).
148. Wall J, Colloton M, Huard J et al.: AMG 655, a monoclonal antibody agonist directed against death receptor 5, induces apoptosis in human colon carcinoma cell lines and its therapeutic potential is enhanced in combination with chemotherapeutic agents, [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research 12-16 April, San Diego, CA, USA. Philadelphia (PA): AACR, (2008) (Abstract 1326).
149. Calzone F, Chaung Y, Cajulis E et al.: Domain-specific mechanisms of receptor inhibition by AMG 479, a fully human IGF1R targeted antibody. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research 12-16 April, San Diego, CA, USA. Philadelphia (PA): AACR, (2008) (Abstract 3994).
150. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH: PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin. Cancer Res. 13, 7380-7387 (2007).
151. Qin A, Watermill J, Mastico R et al.: The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid
152. Clinical.Trials.gov, a service of the US NIH www.ckubucaktruaks.gov